Tert-butyl 3-[[5-[1-(2,3-dihydroxy-4-methylimidazolidin-1-yl)propyl]-1,3,4-oxadiazol-2-yl]methyl]azetidine-1-carboxylate
C18H31N5O5 — CID 123201155
Data last refreshed: (MolForge compound catalog, from PubChem)
About Tert-butyl 3-[[5-[1-(2,3-dihydroxy-4-methylimidazolidin-1-yl)propyl]-1,3,4-oxadiazol-2-yl]methyl]azetidine-1-carboxylate
Tert-butyl 3-[[5-[1-(2,3-dihydroxy-4-methylimidazolidin-1-yl)propyl]-1,3,4-oxadiazol-2-yl]methyl]azetidine-1-carboxylate (PubChem CID 123201155) has the molecular formula C18H31N5O5 and a molecular weight of 397.48 g/mol. Its IUPAC name is tert-butyl 3-[[5-[1-(2,3-dihydroxy-4-methylimidazolidin-1-yl)propyl]-1,3,4-oxadiazol-2-yl]methyl]azetidine-1-carboxylate.
Molecular Properties
| Compound Name | Tert-butyl 3-[[5-[1-(2,3-dihydroxy-4-methylimidazolidin-1-yl)propyl]-1,3,4-oxadiazol-2-yl]methyl]azetidine-1-carboxylate |
|---|---|
| PubChem CID | 123201155 |
| Molecular Formula | C18H31N5O5 |
| Molecular Weight | 397.48 g/mol |
| Exact Mass | 397.23 |
| IUPAC Name | tert-butyl 3-[[5-[1-(2,3-dihydroxy-4-methylimidazolidin-1-yl)propyl]-1,3,4-oxadiazol-2-yl]methyl]azetidine-1-carboxylate |
| SMILES | CCC(c1nnc(CC2CN(C(=O)OC(C)(C)C)C2)o1)N1CC(C)N(O)C1O |
| InChI | InChI=1S/C18H31N5O5/c1-6-13(22-8-11(2)23(26)16(22)24)15-20-19-14(27-15)7-12-9-21(10-12)17(25)28-18(3,4)5/h11-13,16,24,26H,6-10H2,1-5H3 |
| InChIKey | GUKLYMLAZGZDPW-UHFFFAOYSA-N |
| XLogP | 1.60 |
| TPSA | 115.40 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 397.48 |
| LogP ≤ 5 | 1.60 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 123201155 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.